Pharma channel feed

Astel­las wins ap­proval in Japan for Claudin18.2 ther­a­py af­ter US re­jec­tion

Last year
FDA+

Ever­sana to work with pa­tient so­cial net­work to help phar­ma speed time to di­ag­no­sis and treat­ment

Last year
Marketing

Pfiz­er stops one of two Phase 3 tri­als for sick­le cell drug, still plans to seek ap­proval in 2026

Last year
R&D

In­sulin users face short­age with two of Eli Lil­ly's in­sulins through the be­gin­ning of April

Last year
Manufacturing

Mar­ket­ingRx roundup: Phar­ma ad­ver­tis­ers and March Mad­ness; No­vo lands near top of Fast Com­pa­ny's in­no­va­tion list

Last year
Marketing

Phath­om’s first cam­paign for acid block­er Vo­quez­na is the lat­est to use tele­health to reach po­ten­tial pa­tients di­rect­ly

Last year
Marketing

Alex­ion adds fourth in­di­ca­tion for C5 in­hibitor Ul­tomiris in rare au­toim­mune dis­or­der

Last year
R&D

NIH sends BioN­Tech 'no­tice of de­fault' over Covid vac­cine roy­al­ties

Last year
Coronavirus

As­traZeneca ad­vances Fasen­ra's mar­ket­ing with new cam­paign that's on Tik­Tok for first time

Last year
Marketing

J&J's Acte­lion buy­out pays off again with ap­proval of Op­syn­vi in pul­monary ar­te­r­i­al hy­per­ten­sion

Last year
FDA+

Es­pe­ri­on eyes new com­mer­cial push for cho­les­terol-low­er­ing drugs af­ter big FDA la­bel ex­pan­sion

Last year
FDA+

No­vo to buy mid-stage heart fail­ure biotech Car­dior for up to $1.1B

Last year
Startups
Deals

Lead House spon­sor of WuXi-linked bill to leave Con­gress ear­ly

Last year
People
China

FDA to delete 'Y­ou are not a horse' post and oth­ers in iver­mectin case set­tle­ment

Last year
FDA+
Marketing

Leqem­bi au­tho­riza­tion in EU is de­layed for pro­ce­dur­al is­sues

Last year

Seagen’s for­mer com­mer­cial chief joins the board at health­care agency minds + as­sem­bly

Last year
People
Marketing

GSK to part ways with 'most' Bel­lus Health em­ploy­ees a year af­ter $2B buy

Last year
People

Novo's week­ly in­sulin se­cures CHMP thumbs-up as FDA de­ci­sion looms

Last year

FDA ap­proves Ital­far­ma­co’s drug Du­vyzat for Duchenne mus­cu­lar dy­s­tro­phy

Last year
FDA+

Glob­al AIDS pro­gram re­vived in gov­ern­ment spend­ing pack­age as oth­er health rid­ers fall off

Last year
FDA+

Di­a­betes and weight loss drug ad­ver­tis­ing tops $1B on strength of GLP-1 brand spend­ing

Last year
Marketing

Ken­tucky is the fourth state to al­low in­sur­ers to re­quire biosim­i­lar pre­scrip­tions be­fore brand­ed ver­sions

Last year
FDA+

Mer­ck re­ports an­oth­er fail­ure for Keytru­da-Lyn­parza com­bo in non-small cell lung can­cer

Last year
R&D

VML Health part­ners on new key opin­ion leader man­age­ment for bio­phar­mas

Last year
Marketing
First page Previous page 65666768697071 Next page Last page
A service from the Financial Times